ArticleLife (Basel, Switzerland)2025
Comparative Analysis of the Effectiveness of Generic and Brand-Name Cefepime: A Multicenter Retrospective Cohort Study.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does the severity of neutropenia affect mortality in bacteremic cancer patients?BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The clinical effectiveness of generic and brand-name cefepime in real-world settings remains unclear. Given the potential implications for healthcare costs and patient outcomes, this study aims to compare the efficacy and safety of these two formulations. We conducted a multicenter, retrospective cohort study (2017-2022), enrolling adults who received either generic or brand-name cefepime as initial monotherapy for at least three consecutive days. Demographics, comorbidities, disease severity, infection sites, cefepime dosage, and serial laboratory data were analyzed. Propensity score matching was employed to adjust key confounding variables. A total of 2370 patients were included, 877 receiving generic and 1493 receiving brand-name cefepime. After matching, no significant differences were observed in primary (in-hospital mortality,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.